Olufsent (Ezetimibe)

Ezetimibe, the active ingredient in Olufsent, is a lipid‑lowering agent presented as a tablet for oral use. It reduces cholesterol absorption and is used in adults with primary hypercholesterolemia or mixed dyslipidaemia, often together with statins. GNH USA supplies Olufsent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olufsent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olufsent (ezetimibe) acts on cholesterol metabolism pathways to improve lipid profiles.

- Primary hypercholesterolemia: lowers low‑density lipoprotein (LDL) cholesterol levels. - Homozygous familial hypercholesterolemia: provides additional LDL‑cholesterol reduction when combined with other lipid‑lowering therapies. - Mixed dyslipidaemia: decreases LDL cholesterol and modestly lowers triglycerides while raising high‑density lipoprotein (HDL) cholesterol.

Ezetic           … … … … … … … …  … … … … … … … …